Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax (R) for the treatment of adult patients with locally advanced pancreatic cancer concomitant ...

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancerPhase 3 PANOVA-3 trial showed a ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

NovoCure (NVCR) stock rose 29% Thursday on early FDA approval for Optune Pax pancreatic cancer device, prompting H.C. Wainwright to raise target to $47.

Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer ...

NovoCure Ltd NVCR shares are trending on Thursday. Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved Optune Pax ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

Patria Investments (PAX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy) ...

The Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain ...

The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...

A hyperscale data center proposed near Carlisle doesn’t have land development approvals yet, but project leaders have started anteing up to ensure a supply of water. Under terms of an agreement ...